Recruiting
Colorectal cancer metastatic+1
RecruitingStudy of encorafenib and cetuximab treatment for patients with BRAF V600E-mutant metastatic colorectal cancer who previously responded to BRAF inhibitor therapy
Registered drugNo placebo
Study of encorafenib and cetuximab treatment for patients with BRAF V600E-mutant metastatic colorectal cancer who previously responded to BRAF inhibitor therapy
Registered drugNo placebo
- Disease:Colorectal cancer metastaticBRAF V600E mutation positive
- Substances:Encorafenib
Countries:
Spain
Spain- Participants:18–64 years · 65+ years
- Substances:Encorafenib
- Sponsor:Vall D Hebron Institute Of Oncology




